文献速递血栓与止血

艾美赛珠单抗:一种识别凝血因子IX和X的双特异性抗体——它究竟如何与凝血因子VIII相比?

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
PubMed 文献 · Blood · 2017-10-17

本文从生化与机制角度综述艾美赛珠单抗与凝血因子VIII的异同,指出两者虽在促进酶-底物共定位上相似,但蛋白本质与调控方式根本不同;这些认识有助于临床决策,尤其考虑到艾美赛珠单抗与旁路制剂联用时有血栓并发症报告。

要点

  • 艾美赛珠单抗同时结合因子IXa与因子X,模拟FVIII部分功能促进酶-底物共定位。
  • FVIII与双特异性抗体是根本不同的蛋白,受不同调控方式调节。
  • 艾美赛珠单抗与FVIII旁路制剂联用时有血栓并发症报告。

核心结论

  • 艾美赛珠单抗与FVIII在生化与机制上存在相似与不同,这些认识可能有助于目前或未来使用艾美赛珠单抗的临床决策,尤其考虑到其与FVIII旁路制剂联用时有血栓并发症报告。

研究设计与样本

  • 本文为综述,从生化与机制角度概述FVIII与艾美赛珠单抗的异同。

主要发现

  • 近十年血友病A治疗取得进展,包括延长半衰期FVIII(如FVIII-Fc和PEG化FVIII)、靶向组织因子途径抑制物的单克隆抗体、降低抗凝血酶表达的小干扰RNA以及双特异性抗体ACE910/艾美赛珠单抗。
  • 艾美赛珠单抗是同时识别酶因子IXa和底物因子X的双特异性抗体,通过同时结合酶与底物促进酶-底物复合物共定位,从而模拟FVIII的部分功能。
  • FVIII与双特异性抗体是根本不同的蛋白,受不同调控方式调节。
  • 艾美赛珠单抗与FVIII旁路制剂联用时有血栓并发症报告。

临床怎么用

  • 作者认为,了解FVIII与艾美赛珠单抗的相似与不同可能有助于目前或未来使用艾美赛珠单抗者的临床决策,尤其考虑到其与FVIII旁路制剂联用时有血栓并发症报告。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During the last decade, the development of improved and novel approaches for the treatment of hemophilia A has expanded tremendously. These approaches include factor VIII (FVIII) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, small interfering RNA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab. Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa and the substrate factor X. By simultaneously binding enzyme and substrate, emicizumab mimics some part of the function exerted by the original cofactor, FVIII, in that it promotes colocalization of the enzyme-substrate complex. However, FVIII and the bispecific antibody are fundamentally different proteins and subject to different modes of regulation. Here, we will provide an overview of the similarities and dissimilarities between FVIII and emicizumab from a biochemical and mechanistical perspective. Such insight might be useful in the clinical decision making for those who apply emicizumab in their practice now or in the future, particularly in view of the thrombotic complications that have been reported when emicizumab is used in combination with FVIII-bypassing agents.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lenting PJ, Denis CV, Christophe OD, et al. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017. PMID: 29042366. doi:10.1182/blood-2017-08-801662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。